In Silico Evaluation of Lumacaftor for Cystic Fibrosis

Author:

M TEJAS1

Affiliation:

1. The Oxford College of Engineering

Abstract

Abstract

Cystic fibrosis is a common life-limiting autosomal recessive genetic disorder that causes severe damage to lungs, digestive system and other organs in the body. This disease is a result of mutation in a gene that encodes for chloride-conducting transmembrane channel called CFTR, which in turn regulates mucociliary clearance and anion transport in the airways. No effective curative options exist for treatment of Cystic fibrosis. The available drugs exhibit low therapeutic index and can only ease symptoms and reduce complications associated with it. This study aims to evaluate the effectiveness of one such FDA approved drug called Lumacaftor by molecular docking and other in silico studies. The most prevalent CFTR mutation causing cystic fibrosis, ΔF508, impairs folding of nucleotide binding domain 1 and stability of the interface between NBD1. Lumacaftor and drugs like Lumacaftor are modulators 0f F508del-CFTR are responsible for the partial correction of interfacial stability and cellular processing defects. Classification code: I

Publisher

Springer Science and Business Media LLC

Reference16 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3